{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:12:10Z","timestamp":1792699930326,"version":"4.5.0"},"reference-count":98,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.bbadis.2024.167037","type":"journal-article","created":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T11:41:10Z","timestamp":1706701270000},"page":"167037","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Impact of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) on the expression and function of hepatobiliary transporters: A comprehensive mechanistic review"],"prefix":"10.1016","volume":"1870","author":[{"given":"Ankit P.","family":"Laddha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey","family":"Dzielak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cedric","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 E.","family":"Manautou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbadis.2024.167037_bb0005","doi-asserted-by":"crossref","first-page":"482","DOI":"10.2174\/138920009788898037","article-title":"Liver transporters in hepatic drug disposition: An update","volume":"10","author":"Li","year":"2009","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.bbadis.2024.167037_bb0010","series-title":"Regulation of Drug Transport Proteins\u2014From Mechanisms to Clinical Impact: A White Paper on Behalf of the International Transporter Consortium, Clin Pharmacol Ther","first-page":"461","volume":"112","author":"Brouwer","year":"2022"},{"key":"10.1016\/j.bbadis.2024.167037_bb0015","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00210-006-0043-8","article-title":"The solute carrier family SLC10: more than a family of bile acid trans- porters regarding function and phylogenetic relationships","volume":"372","author":"Geyer","year":"2006","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.bbadis.2024.167037_bb0020","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jhep.2013.12.003","article-title":"Hepatic steatosis exacerbated by endoplasmic reticulum stress-mediated downregulation of FXR in aging mice","volume":"60","author":"Xiong","year":"2014","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbadis.2024.167037_bb0025","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1194\/jlr.M700330-JLR200","article-title":"Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine","volume":"48","author":"Kim","year":"2007","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.bbadis.2024.167037_bb0030","doi-asserted-by":"crossref","DOI":"10.1152\/ajpgi.00319.2004","article-title":"Role of nuclear receptors and hepatocyte-enriched transcription factors for Ntcp repression in biliary obstruction in mouse liver","volume":"289","author":"Zollner","year":"2005","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.bbadis.2024.167037_bb0035","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/0092-8674(95)90530-8","article-title":"Identification of a nuclear receptor that is activated by farnesol metabolites","volume":"81","author":"Forman","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.bbadis.2024.167037_bb0040","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1146\/annurev-pharmtox-010617-052713","article-title":"The SLC22 transporter family: a paradigm for the impact of drug transporters on metabolic pathways, signaling, and disease","volume":"58","author":"Nigam","year":"2018","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.bbadis.2024.167037_bb0045","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.pharmthera.2018.10.007","article-title":"Organic anion transporting polypeptide (OATP) transporter expression, localization and function in the human intestine","volume":"195","author":"Oswald","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bbadis.2024.167037_bb0050","series-title":"Protocols in In Vitro Hepatocyte Research Methods in Molecular Biology 1250","author":"Vinken","year":"2015"},{"key":"10.1016\/j.bbadis.2024.167037_bb0055","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1007\/s00424-014-1596-x","article-title":"Differential cellular expression of organic anion transporting peptides OATP1A2 and OATP2B1 in the human retina and brain: implications for carrier-mediated transport of neuropeptides and neurosteriods in the CNS","volume":"467","author":"Gao","year":"2015","journal-title":"Pflugers Arch."},{"key":"10.1016\/j.bbadis.2024.167037_bb0060","doi-asserted-by":"crossref","first-page":"26340","DOI":"10.1074\/jbc.272.42.26340","article-title":"Organic anion transporting polypeptide mediates organic anion\/HCO3-exchange","volume":"272","author":"Satlin","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbadis.2024.167037_bb0065","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1111\/j.1476-5381.2011.01724.x","article-title":"OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies","volume":"165","author":"Roth","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bbadis.2024.167037_bb0070","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1152\/physrev.00025.2013","article-title":"The organic anion transporter (OAT) family: a systems biology perspective","volume":"95","author":"Nigam","year":"2015","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.bbadis.2024.167037_bb0075","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1042\/BJ20061171","article-title":"Determination of the external loops and the cellular orientation of the N- and the C-termini of the human organic anion transporter hOAT1","volume":"401","author":"Hong","year":"2007","journal-title":"Biochem. J."},{"key":"10.1016\/j.bbadis.2024.167037_bb0080","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s004240000297","article-title":"The multispecific organic anion transporter (OAT) family","volume":"440","author":"Sekine","year":"2000","journal-title":"Pflugers Arch."},{"key":"10.1016\/j.bbadis.2024.167037_bb0085","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/MNH.0b013e32830b5d5d","article-title":"Update on the molecular physiology of organic anion transporters","volume":"17","author":"Ahn","year":"2008","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"10.1016\/j.bbadis.2024.167037_bb0090","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1146\/annurev-pharmtox-010617-052713","article-title":"The SLC22 transporter family: a paradigm for the impact of drug transporters on metabolic pathways, signaling, and disease","volume":"58","author":"Nigam","year":"2018","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.bbadis.2024.167037_bb0095","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1124\/dmd.116.072264","article-title":"Organic anion transporter 2: An enigmatic human solute carrier","volume":"45","author":"Shen","year":"2017","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bbadis.2024.167037_bb0100","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1042\/BJ20101904","article-title":"OAT2 catalyses efflux of glutamate and uptake of orotic acid","volume":"436","author":"Fork","year":"2011","journal-title":"Biochem. J."},{"key":"10.1016\/j.bbadis.2024.167037_bb0105","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1124\/mol.110.065201","article-title":"The human organic anion transporter genes OAT5 and OAT7 are transactivated by hepatocyte nuclear factor-1\u03b1 (HNF-1\u03b1)","volume":"78","author":"Klein","year":"2010","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bbadis.2024.167037_bb0110","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/978-3-642-14541-4_3","article-title":"Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy","volume":"201","author":"Nies","year":"2011","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.bbadis.2024.167037_bb0115","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s11095-007-9254-z","article-title":"Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications","volume":"24","author":"Koepsell","year":"2007","journal-title":"Pharm. Res."},{"key":"10.1016\/j.bbadis.2024.167037_bb0120","doi-asserted-by":"crossref","first-page":"452","DOI":"10.2133\/dmpk.20.452","article-title":"Tissue-specific mRNA expression profiles of human ATP-binding cassette and solute carrier transporter superfamilies","volume":"20","author":"Nishimura","year":"2005","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.bbadis.2024.167037_bb0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/pr.109.002014","article-title":"Xenobiotic, bile acid, and cholesterol transporters: function and regulation","volume":"62","author":"Klaassen","year":"2010","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.bbadis.2024.167037_bb0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms10880","article-title":"A phosphotyrosine switch regulates organic cation transporters","volume":"7","author":"Sprowl","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbadis.2024.167037_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107542","article-title":"Novel insights into the organic solute transporter alpha\/beta, OST\u03b1\/\u03b2: from the bench to the bedside","volume":"211","author":"Beaudoin","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bbadis.2024.167037_bb0140","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1124\/dmd.113.055772","article-title":"The roles of MRP2, MRP3, OATP1B1, and OATP1B3 in conjugated hyperbilirubinemia","volume":"42","author":"Keppler","year":"2014","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bbadis.2024.167037_bb0145","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2022.859294","article-title":"Multidrug resistance-associated protein 2 deficiency aggravates estrogen-induced impairment of bile acid metabolomics in rats","volume":"13","author":"Alaei Faradonbeh","year":"2022","journal-title":"Front. Physiol."},{"key":"10.1016\/j.bbadis.2024.167037_bb0150","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1054\/bjoc.2000.1262","article-title":"Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export","volume":"83","author":"Evers","year":"2000","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbadis.2024.167037_bb0155","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1002\/hep.20898","article-title":"Altered disposition of acetaminophen in mice with a disruption of the Mrp3 gene","volume":"42","author":"Manautou","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.bbadis.2024.167037_bb0160","series-title":"Transport of Methotrexate (MTX) and Folates by Multidrug Resistance Protein (MRP) 3 and MRP1 | Cancer Research |","author":"Zeng","year":"2016"},{"key":"10.1016\/j.bbadis.2024.167037_bb0165","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.taap.2007.08.022","article-title":"Induction of Mrp3 and Mrp4 transporters during acetaminophen hepato- toxicity is dependent on Nrf2","volume":"226","author":"Aleksunes","year":"2008","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.bbadis.2024.167037_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/S0022-3565(24)38933-5","article-title":"Altered hepatobiliary disposition of acetaminophen glucuronide in isolated perfused livers from multidrug resistance-associated protein 2-deficient TR\u2212rats","volume":"295","author":"Xiong","year":"2000","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.bbadis.2024.167037_bb0175","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1124\/dmd.31.6.798","article-title":"Hepatobiliary excretion of acetaminophen glutathione conjugate and its derivatives in transport-deficient (TR-) hyperbilirubinemic rats","volume":"31","author":"Chen","year":"2003","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bbadis.2024.167037_bb0180","doi-asserted-by":"crossref","first-page":"10046","DOI":"10.1074\/jbc.273.16.10046","article-title":"The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver","volume":"273","author":"Gerloff","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbadis.2024.167037_bb0185","doi-asserted-by":"crossref","DOI":"10.1152\/ajpgi.2001.281.2.G316","article-title":"Bile salt export pump is highly conserved during vertebrate evolution and its expression is inhibited by PFIC type II mutations","volume":"281","author":"Cai","year":"2001","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.bbadis.2024.167037_bb0190","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1093\/toxsci\/kfq269","article-title":"Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development","volume":"118","author":"Morgan","year":"2010","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.bbadis.2024.167037_bb0195","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S0168-8278(02)00247-7","article-title":"Effects of bile salt flux variations on the expression of hepatic bile salt transporters in vivo in mice","volume":"37","author":"Wolters","year":"2002","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbadis.2024.167037_bb0200","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1124\/mol.105.012104","article-title":"The methyl transferase PRMT1 functions as co-activator of farnesoid X receptor (FXR)\/9-cis retinoid X receptor and regulates transcription of FXR responsive genes","volume":"68","author":"Rizzo","year":"2005","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bbadis.2024.167037_bb0205","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/MPG.0b013e3181596060","article-title":"Update on progressive familial intrahepatic cholestasis","volume":"46","author":"Alissa","year":"2008","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"10.1016\/j.bbadis.2024.167037_bb0210","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1124\/dmd.120.000086","article-title":"A two-tiered in vitro approach to de-risk drug candidates for potential bile salt export pump inhibition liabilities in drug discovery","volume":"48","author":"Hafey","year":"2020","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bbadis.2024.167037_bb0215","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1055\/s-2000-9426","article-title":"Hepatic transport of bile salts","volume":"20","author":"Kullak-Ublick","year":"2000","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.bbadis.2024.167037_bb0220","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1208\/s12248-014-9668-6","article-title":"Role of the breast cancer resistance protein (BCRP\/ABCG2) in drug transport\u2014an update","volume":"17","author":"Mao","year":"2015","journal-title":"AAPS Journal"},{"key":"10.1016\/j.bbadis.2024.167037_bb0225","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1093\/carcin\/bgi139","article-title":"Identification of BCRP as transporter of benzo[a]pyrene conjugates metabolically formed in Caco-2 cells and its induction by Ah-receptor agonists","volume":"26","author":"Ebert","year":"2005","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.bbadis.2024.167037_bb0230","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/bdd.2022","article-title":"TKI combination therapy: strategy to enhance dasatinib uptake by inhibiting Pgp- and BCRP-mediated efflux","volume":"37","author":"D\u2019Cunha","year":"2016","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.bbadis.2024.167037_bb0235","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1124\/mol.111.075143","article-title":"Characterization of the role of ABCG2 as a bile acid transporter in liver and placenta","volume":"81","author":"Blazquez","year":"2012","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bbadis.2024.167037_bb0240","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1124\/dmd.110.034512","article-title":"Role of breast cancer resistance protein in the adaptive response to cholestasis","volume":"38","author":"Mennone","year":"2010","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bbadis.2024.167037_bb0245","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1073\/pnas.90.1.312","article-title":"The multidrug resistance (mdr1) gene product functions as an ATP channel","volume":"90","author":"Abraham","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbadis.2024.167037_bb0250","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1208\/ps010418","article-title":"Comparative studies to determine the selective inhibitors for P-glycoprotein and cytochrome P4503A4","volume":"1","author":"Achira","year":"1999","journal-title":"AAPS PharmSci"},{"key":"10.1016\/j.bbadis.2024.167037_bb0255","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/B978-012373947-6.00562-6","article-title":"Multi drug resistance P glycoprotein and other transporters","author":"de Lange","year":"2007","journal-title":"Encyclopedia of Stress"},{"key":"10.1016\/j.bbadis.2024.167037_bb0260","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/978-3-642-14541-4_6","article-title":"P-glycoprotein: tissue distribution, substrates, and functional consequences of genetic variations","volume":"201","author":"Cascorbi","year":"2011","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.bbadis.2024.167037_bb0265","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1002\/hep.28408","article-title":"MDR3 mutation analysis: a step closer to precision medicine","volume":"63","author":"Bezerra","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.bbadis.2024.167037_bb0270","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1021\/acs.chemrestox.7b00048","article-title":"Evaluating the role of multidrug resistance protein 3 (MDR3) inhibition in predicting drug-induced liver injury using 125 pharmaceuticals","volume":"30","author":"Aleo","year":"2017","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.bbadis.2024.167037_bb0275","series-title":"Bile Acid Metabolism During Development, Fetal and Neonatal Physiology","volume":"2-Volume Set","author":"Karpen","year":"2017"},{"key":"10.1016\/j.bbadis.2024.167037_bb0280","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.bbapap.2008.11.012","article-title":"Multidrug efflux transporters in the MATE family","volume":"1794","author":"Kuroda","year":"2009","journal-title":"Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics"},{"key":"10.1016\/j.bbadis.2024.167037_bb0285","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.bbadis.2024.167037_bb0290","first-page":"851","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis, lancet","volume":"7","author":"Riazi","year":"2022","journal-title":"Gastroenterol. Hepatol."},{"key":"10.1016\/j.bbadis.2024.167037_bb0295","first-page":"209","article-title":"Chronic liver disease","author":"Sharma","year":"2023","journal-title":"Sex\/Gender-Specific Medicine in the Gastrointestinal Diseases"},{"issue":"2","key":"10.1016\/j.bbadis.2024.167037_bb1000","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/apt.17846","article-title":"Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction\u2010associated steatotic liver disease","volume":"59","author":"Loomba","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.bbadis.2024.167037_bb0305","series-title":"Nonalcoholic steatohepatitis","author":"Sharma","year":"2023"},{"key":"10.1016\/j.bbadis.2024.167037_bb0310","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cld.2017.08.003","article-title":"The natural history of nonalcoholic fatty liver disease\u2014an evolving view","volume":"22","author":"Lindenmeyer","year":"2018","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.bbadis.2024.167037_bb0315","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.metabol.2016.01.012","article-title":"Epidemiology and natural history of non-alcoholic fatty liver disease","volume":"65","author":"Fazel","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.bbadis.2024.167037_bb0320","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","article-title":"NAFLD: a multisystem disease","volume":"62","author":"Byrne","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbadis.2024.167037_bb0325","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1053\/gast.2002.33573","article-title":"Nonalcoholic fatty liver disease","volume":"122","author":"Clark","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bbadis.2024.167037_bb0330","doi-asserted-by":"crossref","first-page":"S806","DOI":"10.1007\/s12072-013-9477-5","article-title":"Lean NASH: distinctiveness and clinical implication","volume":"7","author":"Das","year":"2013","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.bbadis.2024.167037_bb0335","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/hep.30908","article-title":"Lean NAFLD: a distinct entity shaped by differential metabolic adaptation","volume":"71","author":"Chen","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.bbadis.2024.167037_bb0340","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cld.2015.10.001","article-title":"Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in the United States and the rest of the world","volume":"20","author":"Sayiner","year":"2016","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.bbadis.2024.167037_bb0345","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.metabol.2016.01.012","article-title":"Epidemiology and natural history of non-alcoholic fatty liver disease","volume":"65","author":"Fazel","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.bbadis.2024.167037_bb0350","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1478-3231.2008.01718.x","article-title":"Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus","volume":"29","author":"Leite","year":"2009","journal-title":"Liver Int."},{"key":"10.1016\/j.bbadis.2024.167037_bb0355","first-page":"274","article-title":"Gender and racial differences in nonalcoholic fatty liver disease, world","volume":"6","author":"Pan","year":"2014","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbadis.2024.167037_bb0360","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1440-1746.2005.04086.x","article-title":"Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults","volume":"21","author":"Park","year":"2006","journal-title":"Journal of Gastroenterology and Hepatology (Australia)"},{"key":"10.1016\/j.bbadis.2024.167037_bb0365","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.jhep.2016.05.020","article-title":"Childhood predictors of adult fatty liver the cardiovascular risk in young Finns study","volume":"65","author":"Suomela","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbadis.2024.167037_bb0370","doi-asserted-by":"crossref","first-page":"4987","DOI":"10.3748\/wjg.v20.i17.4987","article-title":"NAFLD prevalence differs among hispanic subgroups: the multi-ethnic study of atherosclerosis","volume":"20","author":"Fleischman","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.bbadis.2024.167037_bb0375","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1016\/j.xphs.2017.04.053","article-title":"Effect of liver disease on hepatic transporter expression and function","volume":"106","author":"Thakkar","year":"2017","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.bbadis.2024.167037_bb0380","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ejphar.2009.04.002","article-title":"Experimental non-alcoholic fatty liver disease results in decreased hepatic uptake transporter expression and function in rats","volume":"613","author":"Fisher","year":"2009","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bbadis.2024.167037_bb0385","doi-asserted-by":"crossref","first-page":"G829","DOI":"10.1152\/ajpgi.00352.2002","article-title":"Substrate specificities of rat oatp1 and ntcp: implications for hepatic organic anion uptake","volume":"285","author":"Hata","year":"2003","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.bbadis.2024.167037_bb0390","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.0959-9673.2006.00465.x","article-title":"Mouse models in non-alcoholic fatty liver disease and steatohepatitis research","volume":"87","author":"Anstee","year":"2006","journal-title":"Int. J. Exp. Pathol."},{"key":"10.1016\/j.bbadis.2024.167037_bb0395","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.jhep.2005.05.031","article-title":"Characterization of organic anion transporter regulation, glutathione metabolism and bile formation in the obese Zucker rat","volume":"43","author":"Geier","year":"2005","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbadis.2024.167037_bb0400","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/cpt.1699","article-title":"Quantitative proteomics and mechanistic modeling of transporter-mediated disposition in nonalcoholic fatty liver disease","volume":"107","author":"Vildhede","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bbadis.2024.167037_bb0405","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1124\/dmd.111.041012","article-title":"Variations in ATP-binding cassette transporter regulation during the progression of human nonalcoholic fatty liver disease","volume":"39","author":"Hardwick","year":"2011","journal-title":"Drug Metabolism and Disposition"},{"key":"10.1016\/j.bbadis.2024.167037_bb0410","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1124\/mol.104.004481","article-title":"Role of glycosylation in trafficking of Mrp2 in sandwich-cultured rat hepatocytes","volume":"67","author":"Zhang","year":"2005","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bbadis.2024.167037_bb0415","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1111\/liv.13362","article-title":"Impaired N-linked glycosylation of uptake and efflux transporters in human non-alcoholic fatty liver disease","volume":"37","author":"Clarke","year":"2017","journal-title":"Liver Int."},{"key":"10.1016\/j.bbadis.2024.167037_bb0420","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/hep.25630","article-title":"Disruption of phospholipid and bile acid homeostasis in mice with nonalcoholic steatohepatitis","volume":"56","author":"Tanaka","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.bbadis.2024.167037_bb0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2022.111618","article-title":"Discovery of farnesoid X receptor and its role in bile acid metabolism","volume":"548","author":"Chiang","year":"2022","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.bbadis.2024.167037_bb0430","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s40495-017-0085-2","article-title":"Role of FXR in liver inflammation during nonalcoholic steatohepatitis","volume":"3","author":"Armstrong","year":"2017","journal-title":"Curr Pharmacol Rep"},{"key":"10.1016\/j.bbadis.2024.167037_bb0435","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S1665-2681(19)31170-6","article-title":"The nuclear receptor FXR, but not LXR, up-regulates bile acid transporter expression in non-alcoholic fatty liver disease","volume":"14","author":"Aguilar-Olivos","year":"2015","journal-title":"Ann. Hepatol."},{"key":"10.1016\/j.bbadis.2024.167037_bb0440","unstructured":"NIDDK Central Repository - Nonalcoholic Steatohepatitis Clinical Research Network (NASH), (n.d.)."},{"key":"10.1016\/j.bbadis.2024.167037_bb0445","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1007\/s00535-015-1148-y","article-title":"The intrahepatic expression levels of bile acid transporters are inversely correlated with the histological progression of nonalcoholic fatty liver disease","volume":"51","author":"Okushin","year":"2016","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.bbadis.2024.167037_bb0450","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1124\/dmd.113.055996","article-title":"Modeling human nonalcoholic steatohepatitis-associated changes in drug transporter expression using experimental rodent models","volume":"42","author":"Canet","year":"2014","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bbadis.2024.167037_bb0455","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jhep.2014.02.021","article-title":"Synergistic interaction between genetics and disease on pravastatin disposition","volume":"61","author":"Clarke","year":"2014","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbadis.2024.167037_bb0460","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1124\/jpet.114.220764","article-title":"Mechanistic basis of altered morphine disposition in nonalcoholic steatohepatitis","volume":"352","author":"Dzierlenga","year":"2015","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.bbadis.2024.167037_bb0465","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1124\/jpet.113.211284","article-title":"Experimental nonalcoholic steatohepatitis increases exposure to simvastatin hydroxy acid by decreasing hepatic organic anion transporting polypeptide expression","volume":"348","author":"Clarke","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bbadis.2024.167037_bb0470","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/cpt.66","article-title":"Altered morphine glucuronide and bile acid disposition in patients with nonalcoholic steatohepatitis","volume":"97","author":"Ferslew","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bbadis.2024.167037_bb0475","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/cpt.997","article-title":"Transporter-mediated alterations in patients with NASH increase systemic and hepatic exposure to an OATP and MRP2 substrate","volume":"104","author":"Ali","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bbadis.2024.167037_bb0480","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1124\/dmd.117.079624","article-title":"Apixaban and Rosuvastatin pharmacokinetics in nonalcoholic fatty liver disease","volume":"46","author":"Tirona","year":"2018","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bbadis.2024.167037_bb0485","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1124\/dmd.114.062703","article-title":"Altered regulation of hepatic efflux transpor- ters disrupts acetaminophen disposition in pediatric nonalcoholic steatohepatitis","volume":"43","author":"Canet","year":"2015","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bbadis.2024.167037_bb0490","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/cpt.997","article-title":"Transporter-mediated alterations in patients with NASH increase systemic and hepatic exposure to an OATP and MRP2 substrate","volume":"104","author":"Ali","year":"2018","journal-title":"Clin. Pharmacol. Ther."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092544392400022X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092544392400022X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T16:59:29Z","timestamp":1751216369000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092544392400022X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":98,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S092544392400022X"],"URL":"https:\/\/doi.org\/10.1016\/j.bbadis.2024.167037","relation":{},"ISSN":["0925-4439"],"issn-type":[{"value":"0925-4439","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) on the expression and function of hepatobiliary transporters: A comprehensive mechanistic review","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbadis.2024.167037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"167037"}}